From: E-cadherin genetic variants predict survival outcome in breast cancer patients
Characteristics | Disease-free survival | Overall survival | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
Agea | 0.74 | 0.51–1.08 | 0.121 | ni |  |  | 0.75 | 0.33–1.68 | 0.487 | ni |  |  |
Menopausal statusb | 0.92 | 0.66–1.28 | 0.638 | ni |  |  | 0.87 | 0.42–1.76 | 0.702 | ni |  |  |
Tumor sizec | 1.87 | 1.33–2.64 | 0.0003 | 1.80 | 1.27–2.56 | 0.001 | 1.44 | 0.69–3.02 | 0.326 | ni |  |  |
Lymph node involvementd | 1.75 | 1.22–2.51 | 0.002 | 1.66 | 1.14–2.40 | 0.007 | 2.97 | 1.21–7.30 | 0.017 | 3.26 | 1.22–8.69 | 0.018 |
Metastasisd | 3.03 | 1.47–6.22 | 0.003 | ni |  |  | 5.64 | 1.67–19.01 | 0.005 | ni |  |  |
SBR gradee | 1.09 | 0.77–1.56 | 0.599 | ni |  |  | 2.29 | 1.08–4.84 | 0.030 | 2.20 | 1.00–4.81 | 0.048 |
Histologyf | 1.62 | 0.82–3.20 | 0.157 | ni |  |  | 0.80 | 0.11–5.92 | 0.833 | ni |  |  |
Estrogen receptord | 1.34 | 0.91–1.95 | 0.127 | ni |  |  | 0.73 | 0.33–1.60 | 0.435 | ni |  |  |
Progesteron receptord | 1.16 | 0.80–1.67 | 0.419 | ni |  |  | 0.88 | 0.40–1.95 | 0.763 | ni |  |  |
Her-2 statusd | 1.03 | 0.44–2.40 | 0.938 | ni |  |  | 0.67 | 0.06–7.44 | 0.746 | ni |  |  |
CDH1 −347 G/GA g | 0.92 | 0.63–1.35 | 0.694 | ni |  |  | 0.09 | 0.01–0.68 | 0.020 | 0.12 | 0.01–0.89 | 0.039 |
CDH1 −160 C/A g | 0.92 | 0.66–1.28 | 0.650 | ni |  |  | 1.27 | 0.62–2.63 | 0.505 | ni |  |  |
CDH1 +54 C/T g | 0.98 | 0.69–1.40 | 0.951 | ni |  |  | 0.52 | 0.26–1.06 | 0.075 | 0.40 | 0.18–0.87 | 0.022 |